Literature DB >> 17655865

Rearrangement analysis in archival thyroid tissues: punching microdissection and artificial RET/PTC 1-12 transcripts.

Florian Imkamp1, Reinhard von Wasielewski, Thomas J Musholt, Petra B Musholt.   

Abstract

BACKGROUND: In few papillary thyroid carcinomas (PTC) and oxyphilic thyroid carcinoma, the clinical impact of the 15 known RET hybrid oncogene variants (RET/PTC 1 to 12, 1L, 3r2, 3r3) is subject to controversial discussions. Large patient cohorts and exploitation of pathological thyroid tissue archives are essential to study the prognostic significance of RET/PTC chimeras.
MATERIALS AND METHODS: Formalin-fixed and paraffin-embedded thyroid neoplasms were subjected to manual punching macrodissection and subsequent extraction of total RNA. Following reverse transcriptase polymerase chain reaction (RT-PCR)-based screening for RET rearrangements, hybrid-specific expression analyses were carried out for samples indicative of chimeric transcripts. Due to lack of tissue specimen harboring the rare RET chimeras, artificially constructed hybrid sequences of all known RET/PTC variants served as PCR controls.
RESULTS: Manual punching dissection successfully diminished RET wild-type contamination originating from C-cells dispersed throughout normal thyroid tissues. The average amount of 27.4 mug RNA extracted allowed for repeated molecular analyses (>60 PCRs). Hybrid-specific expression analysis identified 10 of 15 RET rearrangements (8x RET/PTC 1, 2x RET/PTC 3, 5x RET/PTC x) to be found in 54 oxyphilic thyroid tumors examined. Successful amplification of each artificial hybrid sequence ensured the absence of rare chimeric transcripts. Therefore, RET/PTC x represent either common chimeras not amplifiable due to archival RNA degradation or truly novel hybrid oncoproducts.
CONCLUSIONS: The fast and simple techniques described here were used to examine oxyphilic carcinomas and adenomas. These microdissection and RT-PCR procedures can easily be put into practice in any molecular biology research laboratory to enable screening of large numbers of archival thyroid tumors for known as well as yet unknown RET rearrangements.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17655865     DOI: 10.1016/j.jss.2006.10.033

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  11 in total

1.  Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension.

Authors:  Julio Ricarte-Filho; Ian Ganly; Michael Rivera; Nora Katabi; Weimin Fu; Ashok Shaha; R Michael Tuttle; James A Fagin; Ronald Ghossein
Journal:  Thyroid       Date:  2012-04-03       Impact factor: 6.568

2.  Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.

Authors:  Michael Rivera; Julio Ricarte-Filho; Jeff Knauf; Ashok Shaha; Michael Tuttle; James A Fagin; Ronald A Ghossein
Journal:  Mod Pathol       Date:  2010-06-04       Impact factor: 7.842

3.  Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.

Authors:  Rebecca E Schweppe; Nikita Pozdeyev; Laura A Pike; Christopher Korch; Qiong Zhou; Sharon B Sams; Vibha Sharma; Umarani Pugazhenthi; Christopher Raeburn; Maria B Albuja-Cruz; Philip Reigan; Daniel V LaBarbera; Iñigo Landa; Jeffrey A Knauf; James A Fagin; Bryan R Haugen
Journal:  Mol Cancer Res       Date:  2019-02-07       Impact factor: 5.852

4.  Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension.

Authors:  Michael Rivera; Julio Ricarte-Filho; Robert Michael Tuttle; Ian Ganly; Ashok Shaha; Jeffrey Knauf; James Fagin; Ronald Ghossein
Journal:  Thyroid       Date:  2010-10       Impact factor: 6.568

5.  Diagnosis and treatment of pancreatic metastases of a papillary thyroid carcinoma.

Authors:  Thomas Borschitz; Waltraud Eichhorn; Christian Fottner; Torsten Hansen; Arno Schad; Simin Schadmand-Fischer; Matthias M Weber; Mathias Schreckenberger; Hauke Lang; Thomas J Musholt
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

6.  Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules.

Authors:  Thomas J Musholt; Christian Fottner; Matthias M Weber; Waltraud Eichhorn; Joachim Pohlenz; Petra B Musholt; Erik Springer; Arno Schad
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

7.  Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.

Authors:  M M Sabra; J M Dominguez; R K Grewal; S M Larson; R A Ghossein; R M Tuttle; J A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

8.  Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.

Authors:  Petra B Musholt; Thomas J Musholt; Saskia C Morgenstern; Karl Worm; Sien-Yi Sheu; Kurt W Schmid
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

9.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Authors:  Julio C Ricarte-Filho; Mabel Ryder; Dhananjay A Chitale; Michael Rivera; Adriana Heguy; Marc Ladanyi; Manickam Janakiraman; David Solit; Jeffrey A Knauf; R Michael Tuttle; Ronald A Ghossein; James A Fagin
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

10.  Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study.

Authors:  Michael Rivera; Julio Ricarte-Filho; Snehal Patel; Michael Tuttle; Ashok Shaha; Jatin P Shah; James A Fagin; Ronald A Ghossein
Journal:  Hum Pathol       Date:  2009-11-13       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.